News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,661 Results
Type
Article (13470)
Company Profile (103)
Press Release (245088)
Section
Business (87798)
Career Advice (459)
Deals (15317)
Drug Delivery (60)
Drug Development (36452)
Employer Resources (49)
FDA (6228)
Job Trends (6180)
News (149686)
Policy (13988)
Tag
Academia (435)
Africa (312)
Alliances (23026)
Alzheimer's disease (321)
Approvals (6213)
Arizona (33)
Artificial intelligence (38)
Asia (19613)
Australia (2530)
Bankruptcy (143)
Best Places to Work (4183)
Biosimilars (31)
Biotechnology (41)
C2C Services and Suppliers (10601)
California (546)
Canada (413)
Cancer (109)
Career advice (401)
Cell therapy (22)
China (58)
Clinical research (29990)
Collaboration (43)
Connecticut (24)
COVID-19 (734)
Cystic fibrosis (21)
Data (64)
Diabetes (22)
Diagnostics (1196)
Drug pricing (47)
Earnings (31136)
Employer resources (43)
Europe (38346)
Events (36206)
Executive appointments (64)
FDA (6288)
Florida (68)
Funding (31)
Gene therapy (37)
GLP-1 (254)
Government (1247)
Healthcare (3497)
Hotbed/Location (177916)
Illinois (65)
Indiana (53)
Infectious disease (737)
Inflammatory bowel disease (40)
Interviews (57)
IPO (5776)
IRA (22)
Job creations (2047)
Job search strategy (371)
Kansas (48)
Layoffs (163)
Legal (3398)
Lung cancer (23)
Manufacturing (41)
Maryland (82)
Massachusetts (496)
Medical device (1251)
Medtech (1252)
Mergers & acquisitions (9468)
Metabolic disorders (90)
Minnesota (34)
Neuroscience (367)
New Jersey (224)
New York (144)
NextGen Class of 2024 (1576)
Non-profit (587)
North Carolina (220)
Northern California (242)
Obesity (56)
Ohio (28)
Opinion (104)
Patents (38)
Pennsylvania (178)
People (28193)
Pharmaceutical (58)
Phase I (7808)
Phase II (12683)
Phase III (11385)
Pipeline (46)
Podcasts (34)
Policy (33)
Postmarket research (1397)
Preclinical (3123)
Press Release (25)
Rare diseases (45)
Real estate (2624)
Regulatory (9685)
Research institute (561)
Resumes & cover letters (55)
South America (496)
Southern California (248)
Startups (1623)
Texas (66)
The Weekly (21)
United States (2462)
Vaccines (86)
Washington State (44)
Weight loss (47)
Date
Last 7 days (205)
Last 30 days (722)
Last 365 days (13333)
2024 (9014)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19035)
2019 (14887)
2018 (11713)
2017 (13890)
2016 (13129)
2015 (15472)
2014 (12421)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,661 Results for "acelrx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
AcelRx Pharmaceuticals, Inc. today announced the rebranding of the Company, with a name change to Talphera, Inc. (“Talphera”).
January 9, 2024
·
6 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
AcelRx Pharmaceuticals, Inc. today announced the publication of a quantitative market research study evaluating current U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury in the intensive care unit.
December 12, 2023
·
8 min read
Biotech Bay
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion on its lead candidate Niyad™ (nafamostat) for use as an anticoagulant in dialysis circuits.
November 7, 2023
·
7 min read
Business
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on Wednesday, November 8, 2023.
October 26, 2023
·
1 min read
Business
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, reported its third quarter 2023 financial results and provided a corporate update.
November 8, 2023
·
11 min read
Biotech Bay
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that it is advancing Niyad™ (a lyophilized formulation of nafamostat) into a registrational study following the recent approval of an Investigational Device Exemption (IDE) submission to the United States Food and Drug Administration (FDA).
October 3, 2023
·
6 min read
Business
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2023 financial results and provided a corporate update.
August 10, 2023
·
12 min read
Biotech Bay
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference - September 6, 2023
AcelRx Pharmaceuticals, Inc. today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.
September 6, 2023
·
1 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).
March 14, 2023
·
9 min read
Biotech Bay
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals.
April 5, 2023
·
6 min read
1 of 25,867
Next